H.W.A. de Bruijn

3.8k citations

66 papers · 2.8k indexed · 1 hit paper · h-index 24

Co-authors: Jan G. Aalders Jitze M. Duk Gert Jan Fleuren Ate G.J. van der Zee Yinhua Yu Robert C. Bast J. Bouma Mindert Krans
Topics: Ovarian cancer diagnosis and treatment (29 papers)Endometrial and Cervical Cancer Treatments (10 papers)Cervical Cancer and HPV Research (10 papers)
Cited by: Reproductive Medicine Obstetrics and Gynecology Spectroscopy
Journals: New England Journal of Medicine Journal of Clinical Oncology Cancer
Partner nations: Netherlands United States United Kingdom

In The Last Decade

H.W.A. de Bruijn

64 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

2004 741 citations Robert C. Bast, Yinhua Yu et al. profile →

Peers

Countries citing papers authored by H.W.A. de Bruijn

Since Specialization

Citations

This map shows the geographic impact of H.W.A. de Bruijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.W.A. de Bruijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.W.A. de Bruijn more than expected).

Fields of papers citing papers by H.W.A. de Bruijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H.W.A. de Bruijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.W.A. de Bruijn. The network helps show where H.W.A. de Bruijn may publish in the future.

Co-authorship network of co-authors of H.W.A. de Bruijn

This figure shows the co-authorship network connecting the top 25 collaborators of H.W.A. de Bruijn. A scholar is included among the top collaborators of H.W.A. de Bruijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H.W.A. de Bruijn. H.W.A. de Bruijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer 2007 ·Gynecologic Oncology ·Zhen Zhang,Yinhua Yu,Fengji Xu,Andrew Berchuck,(unknown),Laura J. Havrilesky,H.W.A. de Bruijn,Ate G.J. van der Zee,Robert Woolas,Ian Jacobs,Steven J. Skates,Daniel W. Chan,Robert C. Bast	80
2	Squamous Cell Carcinoma Antigen Isoforms in Serum from Cervical Cancer Patients 2006 ·Tumor Biology ·(unknown),H.W.A. de Bruijn,(unknown),(unknown),Maria Lundin,Karin Nilsson,(unknown),Olle Nilsson	10
3	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma 2001 ·Cancer ·(unknown),Yu Shen,Fengji Xu,Yinhua Yu,A. Berchuck,Laura J. Havrilesky,H.W.A. de Bruijn,Ate G.J. van der Zee,Robert C. Bast,Neville F. Hacker	87
4	Prognostic Significance of CA 125 and TPS Levels after 3 Chemotherapy Courses in Ovarian Cancer Patients 2000 ·Gynecologic Oncology ·A. van Dalen,Judith Favier,Alexander Burges,U Hasholzner,H.W.A. de Bruijn,(unknown),(unknown),Daniel Fink,M Giai,(unknown),A Harłozińska,(unknown),Janina Markowska,Rafael Molina,C. Sturgeon,A. Bowman,R. Einarsson	45
5	Serum CA 125, Carcinoembryonic Antigen, and CA 19-9 as Tumor Markers in Borderline Ovarian Tumors 2000 ·Gynecologic Oncology ·M.J.A. Engelen,H.W.A. de Bruijn,Harrie Hollema,Klaske A. ten Hoor,(unknown),Jan G. Aalders,Ate G.J. van der Zee	108
6	Ovarian cysts in women receiving tamoxifen for breast cancer 1999 ·British Journal of Cancer ·M J E Mourits,Elisabeth G.E. de Vries,Pax H.B. Willemse,Klaske A. ten Hoor,Harry Hollema,W.J. Sluiter,H.W.A. de Bruijn,Ate G.J. van der Zee	46
7	The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix 1998 ·Tumor Biology ·H.W.A. de Bruijn,Jitze M. Duk,A.G.J. van der Zee,E. Pras,Pax H.B. Willemse,H. Boonstra,Harry Hollema,Marian J.E. Mourits,Elisabeth G.E. de Vries,J.G. Aalders	50
8	Relation between HPV-16 serology and clinico-pathological data in cervical carcinoma patients: prognostic value of anti-E6 and/or anti-E7 antibodies 1997 ·Cancer Immunology Immunotherapy ·Marc Baay,(unknown),Klaas H. Groenier,(unknown),H.W.A. de Bruijn,Harry Hollema,(unknown),Paul Herbrink	10
9	Cell Biological Markers of Drug Resistance in Ovarian Carcinoma 1995 ·Gynecologic Oncology ·Ate G.J. van der Zee,Harrie Hollema,H.W.A. de Bruijn,Pax H.B. Willemse,H. Boonstra,Nanno H. Mulder,Jan G. Aalders,Elisabeth G.E. de Vries	25
10	Concanavalin A Variants of Alpha-Fetoprotein in First Trimester Fetuses with Trisomy 21 and with Normal Karyotypes 1995 ·Gynecologic and Obstetric Investigation ·Frans J. Los,H.C. Janse,Helen Brandenburg,(unknown),H.W.A. de Bruijn	4
11	CA 125 in serum and tumor from patients with uterine sarcoma 1994 ·International Journal of Gynecological Cancer ·Jitze M. Duk,J. Bouma,Gary T. Burger,(unknown),H.W.A. de Bruijn	16
12	Maternal serum CA 125 levels in pregnancies with chromosomally‐normal and ‐abnormal fetuses 1993 ·Prenatal Diagnosis ·J. M. M. van Lith,A. Mantingh,H.W.A. de Bruijn,(unknown)	16
13	Cancer-Associated Antigen CA 195 in Patients with Mucino&ypsilon;s Ovarian Tumours: A Comparative Analysis with CEA, TATI and CA 125 in Serum Specimens and Cyst Fluids 1993 ·Tumor Biology ·H.W.A. de Bruijn,Klaske A. ten Hoor,H. Boonstra,J. Marrink,Mindert Krans,J.G. Aalders	15
14	Second trimester amniocentesis in twin pregnancies: maternal haemoglobin as a dye marker to differentiate diamniotic twins 1992 ·BJOG An International Journal of Obstetrics & Gynaecology ·J. R. Beekhuis,H.W.A. de Bruijn,J. M. M. van Lith,(unknown)	12
15	Endodermal sinus tumor of the ovary during pregnancy: A case report 1991 ·American Journal of Obstetrics and Gynecology ·A.G.J. van der Zee,H.W.A. de Bruijn,J. Bouma,J.G. Aalders,J.W. Oosterhuis,Elisabeth G.E. de Vries	18
16	The effect of abdominal surgery on the serum concentration of the tumour‐associated antigen CA 125 1990 ·BJOG An International Journal of Obstetrics & Gynaecology ·Ate G.J. van der Zee,Jitze M. Duk,Jan G. Aalders,(unknown),Klaske A. ten Hoor,H.W.A. de Bruijn	41
17	Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum ca 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics 1990 ·Cancer ·Jitze M. Duk,H.W.A. de Bruijn,Klaas H. Groenier,Gert Jan Fleuren,Jan G. Aalders	37
18	Serum CA 125 Levels in Patients with a Provisional Diagnosis of Pelvic Inflammatory Disease: Clinical and Theoretical Implications 1989 ·Acta Obstetricia Et Gynecologica Scandinavica ·Jitze M. Duk,(unknown),Gert Jan Fleuren,H.W.A. de Bruijn	20
19	Inhibin as a Marker for Granulosa-Cell Tumors 1989 ·New England Journal of Medicine ·Richard E. Lappöhn,Henry Burger,J. Bouma,Mohan Bangah,Mindert Krans,H.W.A. de Bruijn	249
20	DISCREPANCIES BETWEEN TUMOR-MARKER PROFILES AND DISEASE STATUS IN PATIENTS WITH OVARIAN-CANCER 1984 ·TumorDiagnostik & Therapie ·T Ockhuizen,H.W.A. de Bruijn,Marten S. Schilthuis,Ben G. Szabó,J.G. Aalders	1

About H.W.A. de Bruijn

H.W.A. de Bruijn is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Immunology, having authored 66 papers that have together received 2.8k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (29 papers), Endometrial and Cervical Cancer Treatments (10 papers) and Cervical Cancer and HPV Research (10 papers). The work is most often cited by research in Reproductive Medicine (1.2k citations), Obstetrics and Gynecology (583 citations) and Spectroscopy (492 citations). H.W.A. de Bruijn has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jan G. Aalders, Jitze M. Duk, Gert Jan Fleuren, Ate G.J. van der Zee, Yinhua Yu, Robert C. Bast, J. Bouma, Mindert Krans, Klaske A. ten Hoor and Ian Jacobs. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact